{"protocolSection": {"identificationModule": {"nctId": "NCT01975246", "orgStudyIdInfo": {"id": "1348.1"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Add-on to Micamlo BP Trial", "officialTitle": "An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg"}, "statusModule": {"statusVerifiedDate": "2016-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-11"}, "primaryCompletionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-10-29", "studyFirstSubmitQcDate": "2013-10-29", "studyFirstPostDateStruct": {"date": "2013-11-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-10-06", "resultsFirstSubmitQcDate": "2016-10-06", "resultsFirstPostDateStruct": {"date": "2016-11-29", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-07-23", "dispFirstSubmitQcDate": "2014-07-23", "dispFirstPostDateStruct": {"date": "2014-07-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-10-06", "lastUpdatePostDateStruct": {"date": "2016-11-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/A5 mg."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 309, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Telmisartan+amlodipine+HCTZ", "type": "EXPERIMENTAL", "description": "telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet", "interventionNames": ["Drug: Telmisartan + amlodipine", "Drug: hydrochlorothiazide"]}, {"label": "Telmisartan+amlodipine", "type": "ACTIVE_COMPARATOR", "description": "telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet", "interventionNames": ["Drug: Telmisartan + amlodipine", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Telmisartan + amlodipine", "description": "FDC tablet", "armGroupLabels": ["Telmisartan+amlodipine+HCTZ"]}, {"type": "DRUG", "name": "hydrochlorothiazide", "description": "tablet", "armGroupLabels": ["Telmisartan+amlodipine+HCTZ"]}, {"type": "DRUG", "name": "Telmisartan + amlodipine", "description": "FDC tablet", "armGroupLabels": ["Telmisartan+amlodipine"]}, {"type": "DRUG", "name": "Placebo", "description": "placebo matching hydrochlorothiazide tablet", "armGroupLabels": ["Telmisartan+amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.", "timeFrame": "baseline and week 8"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.", "timeFrame": "baseline and week 8"}, {"measure": "The Proportion of Patients With DBP<90 mmHg and SBP<140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period", "description": "Patients with trough seated DBP =\\>90 mmHg or trough seated SBP \\>=140 mmHg at baseline were analysed.", "timeFrame": "baseline and week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be \\>=90 and \\<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\\<200 mmHg\n* Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion\n* Age 20 years or older\n\nExclusion criteria:\n\n* Patients with known or suspected secondary hypertension\n* Patients with clinically relevant cardiac arrhythmia\n* Congestive heart failure with New York Heart Association (NYHA) functional class III-IV\n* Patients with recent cardiovascular events\n* Patients with recent stroke events\n* Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy\n* Patients with hepatic and/or renal dysfunction\n* Pre-menopausal women who are nursing or pregnant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "100 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1348.1.015 Boehringer Ingelheim Investigational Site", "city": "Atsubetsu-ku,Sapporo,Hokkaido", "country": "Japan"}, {"facility": "1348.1.006 Boehringer Ingelheim Investigational Site", "city": "Bunkyo-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.37517, "lon": 139.92991}}, {"facility": "1348.1.002 Boehringer Ingelheim Investigational Site", "city": "Chiyoda-ku, Tokyo", "country": "Japan"}, {"facility": "1348.1.005 Boehringer Ingelheim Investigational Site", "city": "Chiyoda-ku, Tokyo", "country": "Japan"}, {"facility": "1348.1.031 Boehringer Ingelheim Investigational Site", "city": "Chiyoda-ku, Tokyo", "country": "Japan"}, {"facility": "1348.1.030 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.1.033 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.1.016 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku,Sapporo,Hokkaido", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.1.021 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku,Tokyo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.1.024 Boehringer Ingelheim Investigational Site", "city": "Itabashi-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "1348.1.028 Boehringer Ingelheim Investigational Site", "city": "Itoshima, Fukuoka", "country": "Japan"}, {"facility": "1348.1.027 Boehringer Ingelheim Investigational Site", "city": "Katsushika-ku, Tokyo", "country": "Japan"}, {"facility": "1348.1.001 Boehringer Ingelheim Investigational Site", "city": "Kishiwada, Osaka", "country": "Japan"}, {"facility": "1348.1.009 Boehringer Ingelheim Investigational Site", "city": "Kita-ku, Osaka", "country": "Japan"}, {"facility": "1348.1.029 Boehringer Ingelheim Investigational Site", "city": "Kita-ku, Osaka", "country": "Japan"}, {"facility": "1348.1.014 Boehringer Ingelheim Investigational Site", "city": "Kiyose,Tokyo", "country": "Japan"}, {"facility": "1348.1.003 Boehringer Ingelheim Investigational Site", "city": "Koto-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.66667, "lon": 139.81718}}, {"facility": "1348.1.022 Boehringer Ingelheim Investigational Site", "city": "Mihama-ku, Chiba, Chiba", "country": "Japan"}, {"facility": "1348.1.004 Boehringer Ingelheim Investigational Site", "city": "Miyagino-ku, Sendai, Miyagi", "country": "Japan"}, {"facility": "1348.1.017 Boehringer Ingelheim Investigational Site", "city": "Moriya, Ibaraki", "country": "Japan"}, {"facility": "1348.1.013 Boehringer Ingelheim Investigational Site", "city": "Naka-ku,Yokohama,Kanagawa", "country": "Japan"}, {"facility": "1348.1.018 Boehringer Ingelheim Investigational Site", "city": "Nishi-ku, Fukuoka, Fukuoka", "country": "Japan"}, {"facility": "1348.1.007 Boehringer Ingelheim Investigational Site", "city": "Okinawa, Okinawa", "country": "Japan"}, {"facility": "1348.1.020 Boehringer Ingelheim Investigational Site", "city": "Sakaide, Kagawa", "country": "Japan"}, {"facility": "1348.1.025 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1348.1.026 Boehringer Ingelheim Investigational Site", "city": "Sapporo, Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "1348.1.008 Boehringer Ingelheim Investigational Site", "city": "Suita, Osaka", "country": "Japan"}, {"facility": "1348.1.032 Boehringer Ingelheim Investigational Site", "city": "Suita, Osaka", "country": "Japan"}, {"facility": "1348.1.019 Boehringer Ingelheim Investigational Site", "city": "Takamatsu, Kagawa", "country": "Japan"}, {"facility": "1348.1.023 Boehringer Ingelheim Investigational Site", "city": "Toshima-ku, Tokyo", "country": "Japan"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study is randomised, double-blind, active-control, parallel-group comparison", "groups": [{"id": "FG000", "title": "Telmisartan and Amlodipine+HCTZ", "description": "Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet."}, {"id": "FG001", "title": "Telmisartan+Amlodipine", "description": "Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "149"}, {"groupId": "FG001", "numSubjects": "160"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "145"}, {"groupId": "FG001", "numSubjects": "158"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Other than stated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated Set (TS): The treated set consisted of all patients who were randomised to the double-blind period and took at least 1 dose of the randomised treatment.", "groups": [{"id": "BG000", "title": "Telmisartan and Amlodipine+HCTZ", "description": "Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet."}, {"id": "BG001", "title": "Telmisartan+Amlodipine", "description": "Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "149"}, {"groupId": "BG001", "value": "160"}, {"groupId": "BG002", "value": "309"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.4", "spread": "9.1"}, {"groupId": "BG001", "value": "55.0", "spread": "9.7"}, {"groupId": "BG002", "value": "54.7", "spread": "9.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "52"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "130"}, {"groupId": "BG002", "value": "257"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.", "populationDescription": "Full analysis set (FAS): This analysis set was, conforming to the intent-to-treat principle, defined as all patients i) included in the treated set; and ii) taking measurements of seated DBP at reference baseline and at 1 or more time points during the double-blind period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline and week 8", "groups": [{"id": "OG000", "title": "Telmisartan and Amlodipine+HCTZ", "description": "Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet."}, {"id": "OG001", "title": "Telmisartan+Amlodipine", "description": "Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "160"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.4", "spread": "0.5"}, {"groupId": "OG001", "value": "-4.5", "spread": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The last observation carried forward (LOCF) method was applied for missing data, where the value from the measurements at the closest preceding visit replaced the missing value.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes baseline DBP as a linear covariate, and treatment and center as fixed effects.", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.3", "ciUpperLimit": "-2.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.7"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline and week 8", "groups": [{"id": "OG000", "title": "Telmisartan and Amlodipine+HCTZ", "description": "Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet."}, {"id": "OG001", "title": "Telmisartan+Amlodipine", "description": "Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "160"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.3", "spread": "0.8"}, {"groupId": "OG001", "value": "-6.9", "spread": "0.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The last observation carried forward (LOCF) method was applied for missing data, where the value from the measurements at the closest preceding visit replaced the missing value.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes baseline SBP as a linear covariate, and treatment and center as fixed effects.", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.6", "ciUpperLimit": "-3.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.1"}]}, {"type": "SECONDARY", "title": "The Proportion of Patients With DBP<90 mmHg and SBP<140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period", "description": "Patients with trough seated DBP =\\>90 mmHg or trough seated SBP \\>=140 mmHg at baseline were analysed.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "baseline and week 8", "groups": [{"id": "OG000", "title": "Telmisartan and Amlodipine+HCTZ", "description": "Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet."}, {"id": "OG001", "title": "Telmisartan+Amlodipine", "description": "Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "160"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "51.7", "lowerLimit": "43.3", "upperLimit": "60.0"}, {"groupId": "OG001", "value": "36.9", "lowerLimit": "29.4", "upperLimit": "44.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The Non-completers considered failure (NCF) method was applied for missing data, where missing data due to early discontinuation will be replaced as \"failure\" up to the planned final visit to be reached by all patients.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0051", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Logistic regression model includes treatment and center as fixed effects.", "paramType": "Odds Ratio (OR)", "paramValue": "2.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.2", "ciUpperLimit": "3.4"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first drug administration until 24 hours after the last drug administration, up to 71 days.", "eventGroups": [{"id": "EG000", "title": "Telmisartan and Amlodipine+HCTZ", "description": "Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.", "seriousNumAffected": 0, "seriousNumAtRisk": 149, "otherNumAffected": 36, "otherNumAtRisk": 149}, {"id": "EG001", "title": "Telmisartan+Amlodipine", "description": "Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet", "seriousNumAffected": 0, "seriousNumAtRisk": 160, "otherNumAffected": 14, "otherNumAtRisk": 160}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 160}]}, {"term": "Blood uric acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 160}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 17.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 160}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim, Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "D000077333", "term": "Telmisartan"}, {"id": "C000548840", "term": "Telmisartan amlodipine combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M1770", "name": "Telmisartan", "asFound": "Fixed dose", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M261345", "name": "Telmisartan amlodipine combination", "asFound": "Pressure, pulse", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}